Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q32 Bio Resets As A Public Company With Two Mid-Stage Assets

Executive Summary

The company announced a reverse merger with Homology Medicines that will take the company public while also regaining full rights from Amgen to bempikibart for atopic dermatitis and alopecia areata.

You may also be interested in...

Amgen’s FTC Settlement To Allow $27.8bn Horizon Deal Closure Sets New M&A Precedent

Amgen agreed not to include Horizon’s Tepezza and Krystexxa in rebate bundling deals with payers, among other terms, so the FTC would clear the companies’ merger, giving pharma firms a new consideration in future dealmaking.

Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough

Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.

NYC’s Ambition: Be A Premier Biotech Hub

New York has its eye on becoming a premier biotech hub and is investing heavily in life sciences. Experts weighed in on the positives and drawbacks of the city for biotechs at a new innovation campus called Cure.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts